Breon Inhalation Capsule 25 mcg+100 mcg is a combination medication used for the management of chronic obstructive pulmonary disease (COPD) and asthma. This combination therapy includes a long-acting beta-agonist (LABA) and a corticosteroid, which work together to improve lung function and control respiratory symptoms.
This combination is used for:
| Brand Name | Breon |
|---|---|
| Type | Inhalation Capsule |
| Weight | 25 mcg+100 mcg |
| Generic | Vilanterol Trifenatate + Fluticasone Furoate |
| Manufacturer | ACI Limited |
| Available in | English বাংলা |
Vilanterol is a long-acting beta-agonist (LABA) that works by stimulating beta-2 adrenergic receptors in the airways, leading to bronchodilation and improved airflow. Fluticasone Furoate is a corticosteroid that reduces inflammation by inhibiting the release of inflammatory mediators and suppressing immune responses in the airways. Together, these components help to relieve symptoms and prevent exacerbations of respiratory conditions.
Vilanterol begins to show its bronchodilatory effects within 30 minutes, with peak effects occurring within 3 to 4 hours. Fluticasone Furoate may take several days to weeks of regular use to achieve its full anti-inflammatory effects and maximum symptom control.
Both components of the combination are absorbed through the lungs. Vilanterol has a rapid onset of action with peak plasma levels occurring within 3 to 4 hours. Fluticasone Furoate has a slower absorption rate but provides sustained effects due to its high affinity for corticosteroid receptors in the lungs.
Vilanterol is primarily metabolized in the liver and excreted through the urine. Fluticasone Furoate is also extensively metabolized in the liver, with its metabolites excreted primarily in the feces.
The usual dosage for this combination is:
The medication is administered via inhalation using a specific inhaler device. Patients should follow the instructions provided with the inhaler to ensure proper usage and effective delivery of the medication. It is important to rinse the mouth after use to reduce the risk of oral thrush.
Common side effects include:
Serious side effects may include:
Symptoms of overdose may include severe tachycardia, hypertension, or hypokalemia. In case of overdose, symptomatic treatment and supportive care should be provided. Seek immediate medical attention for severe symptoms.
Precautions should be taken in patients with:
Drug interactions may include:
Use with caution in patients with:
Potential drug interactions include:
Food interactions are minimal. However, taking the medication with food may help reduce gastrointestinal discomfort.
Breon Inhalation Capsule 25 mcg+100 mcg is categorized as a Category C medication for pregnancy. It should be used during pregnancy only if the potential benefits justify the risks to the fetus. Consult a healthcare provider before use.
It is not known whether Vilanterol or Fluticasone Furoate are excreted in human breast milk. Use with caution during lactation and consult a healthcare provider if breastfeeding is planned or ongoing.
In the event of acute overdose, symptoms may include severe tachycardia, tremors, and hypokalemia. Immediate medical attention should be sought. Treatment typically involves symptomatic management and supportive care.
Breon Inhalation Capsule 25 mcg+100 mcg is contraindicated in:
Use the medication as prescribed by your healthcare provider. Do not exceed the recommended dose and ensure proper inhaler technique to maximize effectiveness. Rinse your mouth after each use to prevent oral thrush.
Store the inhaler at room temperature, away from direct sunlight and moisture. Keep out of reach of children. Do not use the inhaler after the expiration date.
The volume of distribution of Vilanterol and Fluticasone Furoate is extensive, indicating distribution throughout body tissues. Vilanterol has a volume of distribution of approximately 3 liters/kg, while Fluticasone Furoate has a large volume of distribution due to its high tissue affinity.
The half-life of Vilanterol is approximately 8 to 12 hours, allowing for once-daily dosing. Fluticasone Furoate has a longer half-life of approximately 24 hours, supporting once-daily administration.
Vilanterol is primarily cleared through hepatic metabolism and renal excretion. Fluticasone Furoate is extensively metabolized in the liver, with its metabolites excreted mainly in the feces.
See in details version Breon Inhalation Capsule 25 mcg+100 mcg also Breon Inhalation Capsule 25 mcg+100 mcg in bangla
Prof. Dr. A.H.M. Towhidul Alam
Gastrointestinal, Pancreato-Biliary, Endoscopic & Laparoscopic Surgeon